Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.

<h4>Background</h4>Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported...

Full description

Saved in:
Bibliographic Details
Main Authors: Kelli N O'Laughlin, Matthew Thompson, Bala Hota, Michael Gottlieb, Ian D Plumb, Anna Marie Chang, Lauren E Wisk, Aron J Hall, Ralph C Wang, Erica S Spatz, Kari A Stephens, Ryan M Huebinger, Samuel A McDonald, Arjun Venkatesh, Nikki Gentile, Benjamin H Slovis, Mandy Hill, Sharon Saydah, Ahamed H Idris, Robert Rodriguez, Harlan M Krumholz, Joann G Elmore, Robert A Weinstein, Graham Nichol, INSPIRE Investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0264260&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850075024323510272
author Kelli N O'Laughlin
Matthew Thompson
Bala Hota
Michael Gottlieb
Ian D Plumb
Anna Marie Chang
Lauren E Wisk
Aron J Hall
Ralph C Wang
Erica S Spatz
Kari A Stephens
Ryan M Huebinger
Samuel A McDonald
Arjun Venkatesh
Nikki Gentile
Benjamin H Slovis
Mandy Hill
Sharon Saydah
Ahamed H Idris
Robert Rodriguez
Harlan M Krumholz
Joann G Elmore
Robert A Weinstein
Graham Nichol
INSPIRE Investigators
author_facet Kelli N O'Laughlin
Matthew Thompson
Bala Hota
Michael Gottlieb
Ian D Plumb
Anna Marie Chang
Lauren E Wisk
Aron J Hall
Ralph C Wang
Erica S Spatz
Kari A Stephens
Ryan M Huebinger
Samuel A McDonald
Arjun Venkatesh
Nikki Gentile
Benjamin H Slovis
Mandy Hill
Sharon Saydah
Ahamed H Idris
Robert Rodriguez
Harlan M Krumholz
Joann G Elmore
Robert A Weinstein
Graham Nichol
INSPIRE Investigators
author_sort Kelli N O'Laughlin
collection DOAJ
description <h4>Background</h4>Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported outcomes with data from digital health records to understand predictors and impacts of SARS-CoV-2 infection.<h4>Methods</h4>INSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of SARS-CoV-2 infection in eight regions across the US. Adults are eligible for enrollment if they are fluent in English or Spanish, reported symptoms suggestive of acute SARS-CoV-2 infection, and if they are within 42 days of having a SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test), regardless of test results. Recruitment occurs in-person, by phone or email, and through online advertisement. A secure online platform is used to facilitate the collation of consent-related materials, digital health records, and responses to self-administered surveys. Participants are followed for up to 18 months, with patient-reported outcomes collected every three months via survey and linked to concurrent digital health data; follow-up includes no in-person involvement. Our planned enrollment is 4,800 participants, including 2,400 SARS-CoV-2 positive and 2,400 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in individuals with and without infection. Patient-reported outcomes include self-reported health function and status, as well as clinical outcomes including health system encounters and new diagnoses.<h4>Results</h4>Participating sites obtained institutional review board approval. Enrollment and follow-up are ongoing.<h4>Conclusions</h4>This study will characterize medium and long-term sequelae of SARS-CoV-2 infection among a diverse population, predictors of sequelae, and their relative risk compared to persons with similar symptomatology but without SARS-CoV-2 infection. These data may inform clinical interventions for individuals with sequelae of SARS-CoV-2 infection.
format Article
id doaj-art-b08a57d0010d4dc89b02a853f1d9aee8
institution DOAJ
issn 1932-6203
language English
publishDate 2022-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-b08a57d0010d4dc89b02a853f1d9aee82025-08-20T02:46:25ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01173e026426010.1371/journal.pone.0264260Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.Kelli N O'LaughlinMatthew ThompsonBala HotaMichael GottliebIan D PlumbAnna Marie ChangLauren E WiskAron J HallRalph C WangErica S SpatzKari A StephensRyan M HuebingerSamuel A McDonaldArjun VenkateshNikki GentileBenjamin H SlovisMandy HillSharon SaydahAhamed H IdrisRobert RodriguezHarlan M KrumholzJoann G ElmoreRobert A WeinsteinGraham NicholINSPIRE Investigators<h4>Background</h4>Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported outcomes with data from digital health records to understand predictors and impacts of SARS-CoV-2 infection.<h4>Methods</h4>INSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of SARS-CoV-2 infection in eight regions across the US. Adults are eligible for enrollment if they are fluent in English or Spanish, reported symptoms suggestive of acute SARS-CoV-2 infection, and if they are within 42 days of having a SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test), regardless of test results. Recruitment occurs in-person, by phone or email, and through online advertisement. A secure online platform is used to facilitate the collation of consent-related materials, digital health records, and responses to self-administered surveys. Participants are followed for up to 18 months, with patient-reported outcomes collected every three months via survey and linked to concurrent digital health data; follow-up includes no in-person involvement. Our planned enrollment is 4,800 participants, including 2,400 SARS-CoV-2 positive and 2,400 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in individuals with and without infection. Patient-reported outcomes include self-reported health function and status, as well as clinical outcomes including health system encounters and new diagnoses.<h4>Results</h4>Participating sites obtained institutional review board approval. Enrollment and follow-up are ongoing.<h4>Conclusions</h4>This study will characterize medium and long-term sequelae of SARS-CoV-2 infection among a diverse population, predictors of sequelae, and their relative risk compared to persons with similar symptomatology but without SARS-CoV-2 infection. These data may inform clinical interventions for individuals with sequelae of SARS-CoV-2 infection.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0264260&type=printable
spellingShingle Kelli N O'Laughlin
Matthew Thompson
Bala Hota
Michael Gottlieb
Ian D Plumb
Anna Marie Chang
Lauren E Wisk
Aron J Hall
Ralph C Wang
Erica S Spatz
Kari A Stephens
Ryan M Huebinger
Samuel A McDonald
Arjun Venkatesh
Nikki Gentile
Benjamin H Slovis
Mandy Hill
Sharon Saydah
Ahamed H Idris
Robert Rodriguez
Harlan M Krumholz
Joann G Elmore
Robert A Weinstein
Graham Nichol
INSPIRE Investigators
Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.
PLoS ONE
title Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.
title_full Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.
title_fullStr Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.
title_full_unstemmed Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.
title_short Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.
title_sort study protocol for the innovative support for patients with sars cov 2 infections registry inspire a longitudinal study of the medium and long term sequelae of sars cov 2 infection
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0264260&type=printable
work_keys_str_mv AT kellinolaughlin studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT matthewthompson studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT balahota studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT michaelgottlieb studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT iandplumb studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT annamariechang studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT laurenewisk studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT aronjhall studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT ralphcwang studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT ericasspatz studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT kariastephens studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT ryanmhuebinger studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT samuelamcdonald studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT arjunvenkatesh studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT nikkigentile studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT benjaminhslovis studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT mandyhill studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT sharonsaydah studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT ahamedhidris studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT robertrodriguez studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT harlanmkrumholz studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT joanngelmore studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT robertaweinstein studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT grahamnichol studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection
AT inspireinvestigators studyprotocolfortheinnovativesupportforpatientswithsarscov2infectionsregistryinspirealongitudinalstudyofthemediumandlongtermsequelaeofsarscov2infection